Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia

Annals of Hematology
Neethu N MenonEmmanuel Katsanis

Abstract

A second allogeneic (allo) hematopoietic cell transplant (HCT) is an important therapeutic consideration for patients relapsing after their first. We conducted a retrospective review of 41 pediatric patients with leukemia that underwent a second allo-HCT at our institution. Overall, 53.7 and 43.9 % of patients were alive and disease-free at 1 and 5 years, respectively, after the second allo-HCT. The factors affecting outcome by both univariate and multivariate analysis were interval between transplants and the use of a myeloablative conditioning (MAC) regimen prior to second transplant. Outcomes were inferior in patients who received their second transplant <6 months from their first HCT when compared to patients in whom the interval between HCTs was 6-12 or more than 12 months. Interval between HCTs was also significant when each type of leukemia (acute lymphoblastic leukemia (ALL) n = 21, acute myelogenous leukemia (AML) n = 11, and chronic myelogenous leukemia (CML) n = 7) was analyzed separately. In univariate analysis, use of the same donor and use of a matched sibling donor resulted in significant improved outcome. There was not a significant association between disease-free survival (DFS) and age, remission status, use o...Continue Reading

References

Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P RadichJ A Hansen
Jun 28, 2003·Pediatrics International : Official Journal of the Japan Pediatric Society·Keiichi IsoyamaUNKNOWN Kanagawa Cord Blood Bank
Dec 4, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Soheil MeshinchiJean E Sanders
Mar 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Meirav KedmiMichael Y Shapira
Nov 19, 2010·Expert Review of Hematology·A John Barrett, Minoo Battiwalla
Mar 1, 2012·Bone Marrow Transplantation·M KatoK Kato
Jul 28, 2013·Journal of Pediatric Hematology/oncology·Hee Won ChuehHong Hoe Koo
Mar 15, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Swati NaikRobert Krance

❮ Previous
Next ❯

Citations

Dec 2, 2017·British Journal of Haematology·Michaela KuhlenChristina Peters
Dec 16, 2020·Pediatric Transplantation·Volkan HazarUNKNOWN Turkish Pediatric Bone Marrow Transplantation Study Group
Mar 21, 2021·Bone Marrow Transplantation·Akshay SharmaBrandon M Triplett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.